Article Text

other Versions

PDF
Original article
Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results
  1. Tim Wyant1,
  2. Tim Leach1,
  3. Serap Sankoh1,
  4. Yuemei Wang1,
  5. Jonathan Paolino2,
  6. Marcela F Pasetti3,
  7. Brian G Feagan4,
  8. Asit Parikh5
  1. 1Takeda Pharmaceuticals International Co, Cambridge, Massachusetts, USA
  2. 2University of Massachusetts Medical School, Worcester, Massachusetts, USA
  3. 3Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
  4. 4Department of Medicine and Department of Epidemiology and Biostatistics, Robarts Clinical Trials, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada
  5. 5Takeda Pharmaceuticals International, Inc, Deerfield, Illinois, USA
  1. Correspondence to Dr Tim Wyant, Takeda Pharmaceuticals International Co, 40 Landsdowne St, Cambridge, MA 02139, USA; Tim.Wyant{at}takeda.com

Abstract

Objective The α4β7 integrin monoclonal antibody vedolizumab is hypothesised to be gut selective. Effects of vedolizumab on immune responses to parenterally or enterally administered antigens were investigated.

Design In this randomised, double-blind, placebo-controlled, phase I trial, healthy participants received a single intravenous dose of vedolizumab 750 mg (n=64) or placebo (n=63). After 4 days, participants began intramuscular hepatitis B vaccine (HBV; days 4, 32, 60) and oral cholera vaccine (OCV; days 4, 18) regimens. The study was designed to demonstrate a 15% non-inferiority margin for the between-group difference in the primary end point: percentage of participants with HBV seroconversion at day 74 (serum hepatitis B surface antigen (HBs) antibody titre ≥10 IU/L). OCV seroconversion at day 74 (>4-fold increase in serum cholera toxin (CT) antibodies) was a secondary end point.

Results A total of 56 (90.3%) placebo-treated and 54 (88.5%) vedolizumab-treated participants responded to HBV. Geometric mean anti-HBs titres were similar for placebo (114.4 IU/L) and vedolizumab (129.6 IU/L) at day 74. A total of 60 (96.8%) placebo-treated and 52 (82.5%) vedolizumab-treated participants responded to OCV at day 74. Geometric mean anti-CT IgG levels were higher for placebo than for vedolizumab at day 74 (9210.08 vs 3007.8 ELISA Units (EU)/mL) and day 32 (11629.3 vs 1575.4 EU/mL). Anti-CT IgA results were similar. Adverse events were consistent with previous experience. One serious adverse event (spontaneous abortion) was reported for placebo.

Conclusions Vedolizumab did not alter the response to parenterally administered antigens but reduced the response to oral antigens, demonstrating its gut-selective mechanism of action.

Trial registration number NCT Number: 01981616; EudraCT Number: 2011-001874-24.

  • Gut Immunology
  • Antibody Targeted Therapy
  • Inflammatory Bowel Disease

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles